DrugPatentWatch Database Preview
ANGIOMAX Drug Profile
Which patents cover Angiomax, and when can generic versions of Angiomax launch?
The generic ingredient in ANGIOMAX is bivalirudin. There are thirteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for ANGIOMAX
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 32 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,439 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | ANGIOMAX at DailyMed |
Pharmacology for ANGIOMAX
| Drug Class | Anti-coagulant Direct Thrombin Inhibitor |
| Mechanism of Action | Thrombin Inhibitors |
Synonyms for ANGIOMAX
| (R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine |
| 128270-60-0 |
| 270B600 |
| 70B600 |
| 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone |
| AKOS015994644 |
| AM006888 |
| AN-7543 |
| Angiomax (TN) |
| Angiox |
| BC657176 |
| BG 8967 |
| BG-8967 |
| BG8967 |
| Bivalirudin |
| Bivalirudin [USAN:BAN:INN] |
| Bivalirudin [USAN:INN:BAN] |
| Bivalirudin Trifluoacetate |
| Bivalirudin Trifluoroacetate |
| bivalirudina |
| bivalirudine |
| bivalirudinum |
| C98H138N24O33 |
| C9H11NO.C2H6.CH4 |
| CHEBI:59173 |
| CHEMBL2103749 |
| D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leuci |
| D03ZVY |
| D09FGS |
| D09HVL |
| D0F4HO |
| DB00006 |
| EBD32115 |
| GTPL6470 |
| Hirulog |
| Hirulog-1 |
| HS-2004 |
| J-005587 |
| KS-00002WUN |
| L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyro |
| LS-172701 |
| MolPort-006-167-455 |
| Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen |
| Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu |
| Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64) |
| SCHEMBL25739 |
| The Medicines Company brand of bivalirudin |
| TN9BEX005G |
| UNII-TN9BEX005G |
US Patents and Regulatory Information for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The Medicines Co | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| The Medicines Co | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| The Medicines Co | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ANGIOMAX
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
